I can understand that, but maybe I'll ask the same question to Crawford & Company. In your opinion, given the information that we're getting today plus the fact that in 2014 the WHO actually recommended that genetic testing and clinical genetic evaluations be done to help diagnose thalidomide embryopathy where possible, if you were going to look at the criteria, given this information, what could be done better to assess the rejected claimants?
On May 9th, 2017. See this statement in context.